Call us today 212-583-0100

ENZO Biochem to Present at Needham & Company Third Annual Biotechnology Conference

NEW YORK, NY, June 10, 2004 – Enzo Biochem, Inc. (NYSE:ENZ), a leading biotechnology company specializing in gene identification and genetic and immune regulation technologies for diagnostic and therapeutic applications, will make a presentation at the Needham & Company Third Annual Biotechnology Conference in New York City, on Thursday, June 17, 2004, at 11:00 A.M. E.T.
 
 Barry Weiner, President, will make the presentation.
 
The audio portion of the presentation can be accessed via the Internet at http://www.wsw.com/webcast/needham8/enz. Please go to the web site at least fifteen minutes early to register, download and install any necessary audio software. A replay will be available on the website for two weeks following the presentation.
 
About Enzo
 
Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community.  The Company’s proprietary labeling and detection products for gene sequencing and genetic analysis, with over 180 patents worldwide, are sold to the life sciences market throughout the world.  The Company’s therapeutic division is conducting clinical trials for HIV-1 infected patients and for patients infected with hepatitis B and hepatitis C viruses.  The Company also holds a patent covering a method and materials for correcting point mutations, or small insertions or deletions of genetic material, that would allow for editing and correcting certain abnormalities in genes.
 
Except for historical information, the matters discussed in this news release may be considered “forward looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  Such statements include declarations regarding the intent, belief or current expectations of the Company and its management.  Investors are cautioned that any such forward looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.  The Company disclaims any obligations to update any forward-looking statements as a result of developments occurring after the date of this press release.